Rapamycin could increase the effects of melatonin against age-dependent bone loss.

Tao, Zhou-Shan; Lu, Han-Li; Ma, Neng-Feng; Zhang, Rou-Tian; Li, Yang; Yang, Min; Xu, Hong-Guang

Previous studies have demonstrated the beneficial effect of melatonin (MEL) on bone tissue and bone metabolism. Rapamycin (RAP) promotes osteoblast proliferation and inhibits osteoclast proliferation, and positively affects bone regeneration; however, reports about effects of RAP on bone loss for aged female rats with MEL administration are limited. This study investigated the impact of treatment with RAP on bone loss for aged female rats with MEL administration. Female Sprague-Dawley rats weighing approximately 520 g were randomly divided into 3 groups of 10: group CON, group MEL and group MEL RAP and received saline, MEL, RAP plus MEL treatment until death at 12 weeks, respectively. The results of maintaining bone mass and bone strength with RAP plus MEL administration were evaluated by histology, microcomputerized tomography (Micro-CT), gene expression analysis and biomechanical testing. Results from this study indicated that MEL RAP had stronger effects on the prevention and treatment of osteoporosis than MEL administration. Administration of MEL RAP produced the strongest effects on bone parameters and strength for distal femurs and regulation of OPG/RANKL signalling pathway-related gene expression. These results seemed to indicate that RAP could increase the effects of MEL on age-dependent bone loss.

RAPAMYCIN; MELATONIN; OSTEOPENIA; OSTEOPOROSIS treatment; BONE metabolism

Zeitschrift für Gerontologie und Geriatrie, 2020, Vol 53, Issue 7, p671

0948-6704

Academic Journal

10.1007/s00391-019-01659-4